Budde LE, Zhang H, Kim WS, Maruyama D, et al. Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. J Clin Oncol 2025 Oct 2:101200JCO2501957. doi: 10.1200/JCO-25-01957.
PMID: 41037766